Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 December;58(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 December;58(4):344-54

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  PET IN NEURODEGENERATIVE DISORDERS


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2014 December;58(4):344-54

language: English

Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new?

Quartuccio N. 1, Van Weehaeghe D. 2, Cistaro A. 3, 4, 5, Jonsson C. 6, Van Laere K. 2, Pagani M. 5, 6

1 Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphologic and Functional Images, University of Messina, Italy;
2 Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and University Hospital Leuven, Leuven, Belgium;
3 Positron Emission Tomography Centre, IRMET S.p.A., Euromedic Inc., Turin, Italy;
4 PET Pediatric AIMN InterGroup, Turin Italy;
5 Institute of Cognitive Sciences and Technologies, CNR, Rome, Italy;
6 Department of Nuclear Medicine, Karolinska Hospital, Stockholm, Sweden


FULL TEXT  


Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease involving upper and lower motor neurons, extra-motor neurons, microglia and astrocytes. The neurodegenerative process results in progressive muscle paralysis and even in cognitive impairment. Within the complex diagnostic work-up, positron emission tomography (PET) represents a valuable imaging tool in the assessment of patients with ALS. PET, by means of different radiotracers (i.e. 18F-fluorodeoxyglucose, 6-[18F]fluoro-L-dopa, [11C]flumazenil) can assess the status of the wide range of brain regions and neural circuits, which can be affected by ALS. Furthermore, experimental radiocompounds have been developed for the evaluation of white matter, which plays a role in the progression of the disease. Here we present a comprehensive review including in different sections the most relevant PET studies: studies investigating ALS and ALS-mimicking conditions (especially primary lateral sclerosis and other neurodegenerative diseases), articles selecting specific subsets of patients (with bulbar or spinal onset), studies investigating patients with familial type of ALS, studies evaluating the role of the white matter in ALS and papers evaluating the diagnostic sensitivity of PET in ALS patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail

marco.pagani@istc.cnr.it